"Trastuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
| Descriptor ID |
D000068878
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.875 D12.776.124.790.651.114.224.060.875 D12.776.377.715.548.114.224.200.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trastuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Trastuzumab [D12.776.124.486.485.114.224.060.875]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Trastuzumab [D12.776.124.790.651.114.224.060.875]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Trastuzumab [D12.776.377.715.548.114.224.200.875]
Below are MeSH descriptors whose meaning is more specific than "Trastuzumab".
This graph shows the total number of publications written about "Trastuzumab" by people in this website by year, and whether "Trastuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trastuzumab" by people in Profiles.
-
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190.
-
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PLoS One. 2020; 15(6):e0234146.
-
Trastuzumab-induced cardiac toxicity: Is serial assessment of left ventricular ejection fraction during treatment necessary? Breast J. 2020 05; 26(5):1085-1086.
-
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
-
Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016 Sep 01; 2(9):1123-4.
-
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Aug; 74(2):399-410.
-
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther. 2011 Jan 15; 11(2):263-76.
-
Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer. Genes Chromosomes Cancer. 2007 Apr; 46(4):397-405.
-
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70.
-
A case of herceptin cardiotoxicity. Am J Ther. 2004 Jan-Feb; 11(1):74-6.